1 2 3 4 5 6 7

Products

Description

FINEHART® offers the dual combination of Fenofibrate and Atorvastatin, the lipid lowering agents, belonging to a class called Fibrates and Statins respectively. Fenofibrate and Atorvastatin are the most preferred therapies in their respective classes.

Fenofibrate mainly reduces the elevated levels of TG (Triglycerides) whereas Atorvastatin majorly targets the reduction of Cholesterol. Apart from lipid reduction FINEHART® also exerts significant pleiotropic (non-lipid lowering) effects like reduction in the pro-inflammatory markers like CRP, TNF-α, IL-6 etc., which further helps in the reduction of cardiac risks in diabetic and / or dyslipidaemic patients.

FINEHART® , thus, offers blanket coverage over the elevated levels of lipids. This makes FINEHART® a synergistic therapy in Combined Dyslipidaemia reducing TG and Cholesterol, both of which are otherwise independent risk factors for various cardiac complications.

Moreover, there are various studies available that have proved the need of therapy like FINEHART® even in Type 2 diabetics to control lipid levels at the early stage, thereby minimizing the occurrence of future cardiac complications.

Moreover, various studies have proved that FINEHART® is useful in Type 2 diabetics to control lipid levels at the early stage, thereby minimizing the occurrence of future cardiac complications.

FINEHART® - TABLETS

(LIPID LOWERING AGENT - COMBINATION)

click for enlarged image

Composition

FINEHART®

Each film coated tablet contains:
Fenofibrate I.P. .............................................................200 mg.
(in micronised form)
Atorvastatin Calcium I.P.
equivalent to Atorvastatin..............................................10 mg
Excipients ..................................................................... q.s.
Colour : Titanium Dioxide I.P.